Pharmacological Identification of a Guanidine-Containing β-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1)

[1]  B. Frølund,et al.  Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABA(A) receptor agonists. , 2014, European journal of medicinal chemistry.

[2]  Adam J Pawson,et al.  The Concise Guide to Pharmacology 2013/14: Transporters , 2013, British journal of pharmacology.

[3]  A. Schousboe,et al.  Discovery of a subtype selective inhibitor of the human betaine/GABA transporter 1 (BGT-1) with a non-competitive pharmacological profile. , 2013, Biochemical Pharmacology.

[4]  K. Obata.  Synaptic inhibition and γ-aminobutyric acid in the mammalian central nervous system , 2013, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[5]  Arne Schousboe,et al.  Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization. , 2013, Journal of medicinal chemistry.

[6]  David J. Nutt,et al.  GABA system dysfunction in autism and related disorders: From synapse to symptoms , 2012, Neuroscience & Biobehavioral Reviews.

[7]  K. Wanner,et al.  Development of an (S)‐1‐{2‐[Tris(4‐methoxyphenyl)methoxy]ethyl}piperidine‐3‐carboxylic acid [(S)‐SNAP‐5114] Carba Analogue Inhibitor for Murine γ‐Aminobutyric Acid Transporter Type 4 , 2012, ChemMedChem.

[8]  G. Höfner,et al.  Synthesis and pharmacological properties of new GABA uptake inhibitors , 2012, Pharmacological reports : PR.

[9]  Olivier Taboureau,et al.  A Steered Molecular Dynamics Study of Binding and Translocation Processes in the GABA Transporter , 2012, PloS one.

[10]  N. Danbolt,et al.  The betaine-GABA transporter (BGT1, slc6a12) is predominantly expressed in the liver and at lower levels in the kidneys and at the brain surface. , 2012, American journal of physiology. Renal physiology.

[11]  Hanns Möhler,et al.  The GABA system in anxiety and depression and its therapeutic potential , 2012, Neuropharmacology.

[12]  U. Gether,et al.  SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation , 2011, Pharmacological Reviews.

[13]  A. Schousboe,et al.  Selective GABA Transporter Inhibitors Tiagabine and EF1502 Exhibit Mechanistic Differences in Their Ability to Modulate the Ataxia and Anticonvulsant Action of the Extrasynaptic GABAA Receptor Agonist Gaboxadol , 2011, Journal of Pharmacology and Experimental Therapeutics.

[14]  D. Rusakov,et al.  Deletion of the betaine–GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice , 2011, Epilepsy Research.

[15]  M. Mula.  GABAergic drugs in the treatment of epilepsy: modern or outmoded? , 2011, Future medicinal chemistry.

[16]  A. Schousboe,et al.  GABA transport inhibitors and seizure protection: the past and future. , 2011, Future medicinal chemistry.

[17]  Jing-Qiong Kang,et al.  Mutations in GABAA receptor subunits associated with genetic epilepsies , 2010, The Journal of physiology.

[18]  A. Schousboe,et al.  Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. , 2010, Pharmacology & therapeutics.

[19]  H. Bräuner‐Osborne,et al.  The four human gamma-aminobutyric acid (GABA) transporters: pharmacological characterization and validation of a highly efficient screening assay. , 2009, Combinatorial chemistry & high throughput screening.

[20]  A. Schousboe,et al.  Inhibition of the betaine-GABA transporter (mGAT2/BGT-1) modulates spontaneous electrographic bursting in the medial entorhinal cortex (mEC) , 2008, Epilepsy Research.

[21]  A. Meinild,et al.  Cloning and Characterization of a Functional Human γ-Aminobutyric Acid (GABA) Transporter, Human GAT-2* , 2007, Journal of Biological Chemistry.

[22]  Arne Schousboe,et al.  Structure-activity relationships of selective GABA uptake inhibitors. , 2006, Current topics in medicinal chemistry.

[23]  K. Wanner,et al.  Novel parent structures for inhibitors of the murine GABA transporters mGAT3 and mGAT4. , 2005, European journal of pharmacology.

[24]  Istvan Mody,et al.  GABA Transporter Deficiency Causes Tremor, Ataxia, Nervousness, and Increased GABA-Induced Tonic Conductance in Cerebellum , 2005, The Journal of Neuroscience.

[25]  Arne Schousboe,et al.  Selective inhibitors of GABA uptake: synthesis and molecular pharmacology of 4-N-methylamino-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol analogues. , 2005, Bioorganic & medicinal chemistry.

[26]  Scott Slough,et al.  First Demonstration of a Functional Role for Central Nervous System Betaine/γ-Aminobutyric Acid Transporter (mGAT2) Based on Synergistic Anticonvulsant Action among Inhibitors of mGAT1 and mGAT2 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[27]  F. Conti,et al.  GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications , 2004, Brain Research Reviews.

[28]  A. A. Jensen,et al.  Pharmacological characterization of human excitatory amino acid transporters EAAT1, EAAT2 and EAAT3 in a fluorescence-based membrane potential assay. , 2004, Biochemical pharmacology.

[29]  H. Lester,et al.  GABA transporter-1 (GAT1)-deficient mice: differential tonic activation of GABAA versus GABAB receptors in the hippocampus. , 2003, Journal of neurophysiology.

[30]  Arne Schousboe,et al.  Correlation between Anticonvulsant Activity and Inhibitory Action on Glial γ-Aminobutyric Acid Uptake of the Highly Selective Mouse γ-Aminobutyric Acid Transporter 1 Inhibitor 3-Hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and ItsN-Alkylated Analogs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[31]  C. Gottesmann,et al.  GABA mechanisms and sleep , 2002, Neuroscience.

[32]  N. O. Dalby.  GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors , 2000, Neuropharmacology.

[33]  P. Krogsgaard‐Larsen,et al.  GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. , 2000, Current pharmaceutical design.

[34]  K. Fuchs,et al.  Structure and subunit composition of GABAA receptors , 1999, Neurochemistry International.

[35]  N. Nelson,et al.  Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain [corrected]. , 1993, The Journal of biological chemistry.

[36]  P. Suzdak,et al.  Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. , 1991, European journal of pharmacology.

[37]  J. Miller,et al.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system , 1987, Molecular and cellular biology.

[38]  A. Schousboe,et al.  GABA Neurotransmission: An Overview , 2008 .

[39]  Abel Lajtha,et al.  Handbook of Neurochemistry and Molecular Neurobiology , 2007 .

[40]  T. Branchek,et al.  Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site. , 1994, Receptors & channels.